RxDoctor Payments Data

Jill Bryant

Internal Medicine · Joplin, MONPI 1053925537

Payments from drug & device makers

$9,563in general payments, 2019–2025

Across 472 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Axsome Therapeutics, Inc.$849
  • AbbVie$816
  • Lilly USA, LLC$776
  • Novo Nordisk$608
  • Otsuka America Pharmaceutical, Inc.$515
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,48199%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,563 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$262
Medicare patients
14
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$59,867
EliquisApixaban65$47,217
JanuviaSitagliptin Phosphate36$34,095
OzempicSemaglutide23$31,635
FarxigaDapagliflozin Propanediol20$27,860
TrulicityDulaglutide16$25,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,175
XareltoRivaroxaban12$15,977
TradjentaLinagliptin19$14,210
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,465
ArexvyRsvpref3 Antigen/As01e/Pf28$7,585
V-Go 40Sub-Q Insulin Device, 40 Unit14$7,153
Combivent RespimatIpratropium/Albuterol Sulfate11$7,116
Levemir FlexpenInsulin Detemir13$5,600
SymbicortBudesonide/Formoterol Fumarate24$5,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$224$81,19390 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,891$49,62569 claims
PfizerEliquis$69$47,21765 claims
Novo NordiskOzempic, Novolog$608$34,31335 claims
MerckJanuvia$164$34,09536 claims
Lilly USA, LLCTrulicity$776$25,82416 claims
GSKAnoro Ellipta, Arexvy$136$16,04939 claims
Johnson & JohnsonXarelto$492$15,97712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →